» Articles » PMID: 38596782

Fatigue in Prostate Cancer: A Roundtable Discussion and Thematic Literature Review

Overview
Date 2024 Apr 10
PMID 38596782
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Cancer and its treatments cause fatigue in up to 90% of men with advanced prostate cancer. As men with prostate cancer are surviving longer, cancer-related fatigue is becoming increasingly important for clinicians to understand and proactively manage.

Objective: The aim of this work is to identify knowledge gaps that may support healthcare professionals to recommend personalised fatigue management strategies.

Evidence Acquisition: This manuscript is based on a roundtable discussion held during the European Association of Urology 2022 Annual Symposium, combined with a review of the literature. Five core themes were generated from the roundtable: (1) meaning of fatigue in prostate cancer patients, (2) impact of fatigue, (3) association between fatigue and treatment selection, (4) benefits of managing fatigue, and (5) barriers to exercise.

Evidence Synthesis: Cancer-related fatigue has complex underlying aetiology and is a subjective experience that may be under-reported. Some studies have shown that techniques such as education, cognitive behavioural therapy, guided imagery, and progressive muscle relaxation can result in clinically meaningful improvements in fatigue. However, the largest body of evidence, and a theme echoed in the roundtable discussions, was the benefit of exercise on fatigue. Despite the benefits of exercise, for some men, objective barriers to exercise exist and knowledge of benefits does not automatically translate into implementation and adherence.

Conclusions: Understanding the specific health needs of individual patients and their desired health outcomes is essential to identify personalised strategies for minimising fatigue. As an outcome of the roundtable meeting, we developed a quick reference guide for healthcare providers. A high-resolution copy can be downloaded from https://patients.uroweb.org/library/fatigue-in-prostate-cancer-patients-guide/.

Patient Summary: This article is based on dialogue between a group of specialists, patients, and caregivers, which took place at a roundtable meeting during the European Association of Urology 2022 Annual Symposium. The group discussed how healthcare providers can best support their patients who experience fatigue. The group subsequently developed a guide to help healthcare providers during appointments.

Citing Articles

Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.

Thomson A, Gunn L, Victor D, Adamson E, Thakrar K Res Rep Urol. 2024; 16:245-252.

PMID: 39399307 PMC: 11471072. DOI: 10.2147/RRU.S485238.

References
1.
Jian T, Zhan Y, Hu K, He L, Chen S, Hu R . Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Front Pharmacol. 2022; 13:955925. PMC: 9582339. DOI: 10.3389/fphar.2022.955925. View

2.
James N, Clarke N, Cook A, Ali A, Hoyle A, Attard G . Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022; 151(3):422-434. PMC: 9321995. DOI: 10.1002/ijc.34018. View

3.
Ferro M, Di Lorenzo G, de Cobelli O, Bruzzese D, Pignataro P, Borghesi M . Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. World J Urol. 2018; 37(6):1049-1059. DOI: 10.1007/s00345-018-2579-x. View

4.
Luo Y, Yang Y, Wu C, Wang C, Li W, Zhang H . Fatigue prevalence in men treated for prostate cancer: A systematic review and meta-analysis. World J Clin Cases. 2021; 9(21):5932-5942. PMC: 8316927. DOI: 10.12998/wjcc.v9.i21.5932. View

5.
Baguley B, Adlard K, Jenkins D, Wright O, Skinner T . Mediterranean Style Dietary Pattern with High Intensity Interval Training in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Pilot Randomised Control Trial. Int J Environ Res Public Health. 2022; 19(9). PMC: 9099512. DOI: 10.3390/ijerph19095709. View